Vitamin D Supplementation for Treatment of Heart Failure

• Status: Terminated
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The central objective of this proposal is to establish that vitamin D supplementation in heart failure patients with low vitamin D levels will have improved outcomes compared to placebo. In addition the investigators will also evaluate the role of genetics in regard to vitamin D and heart failure. The investigators will be evaluating what is currently a novel approach of identifying patients with low vitamin D and treating this low vitamin D level. The investigators will be able to evaluate the importance of vitamin D supplementation in these patients and the role of genetics on our defined outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Michigan
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• HF patients with LV systolic dysfunction of ischemic or non-ischemic origin and an LVEF <40% using nuclear ventriculography or echocardiography within the last 6 months.

• Attempts should have been made at optimizing medical therapy and the participant should be stable on these medications for at least 3 months.

• Patients with a 25(OH)D level between 10-25 ng/ml

Exclusion Criteria:

• Inability to give informed consent

• Patients with sarcoidosis or other granulomatous disease that can alter vitamin D metabolism

• Patients with primary valvular HF, hypertrophic cardiomyopathy, and drug-induced HF

• Renal dysfunction defined as serum creatinine > 2.5 mg/dl

• Pregnant women

• Patients <18 years of age

• Patients on vitamin D supplementation